)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Acrivon Therapeutics (ACRV) investor relations material
Acrivon Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Focused on developing precision oncology therapies using the AP3 platform, with lead assets ACR-368 (CHK1/CHK2 inhibitor) in Phase 2 for endometrial cancer and ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1 for solid tumors predicted sensitive by AP3.
ACR-368 is in a registrational-intent Phase 2b trial for endometrial cancer, targeting patients with high unmet need, and received FDA Fast Track and Breakthrough Device designations.
Interim Phase 2 data for ACR-368 showed a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature-positive endometrial cancer patients.
ACR-2316 demonstrated significant drug target engagement and initial clinical activity, including tumor shrinkage and a confirmed partial response at sub-therapeutic doses.
Showcased AP3 platform's capabilities at a major oncology conference, highlighting its role in rational drug design.
Financial highlights
Net loss for Q3 2025: $18.2 million, improved from $22.4 million in Q3 2024.
Net loss for the nine months ended September 30, 2025: $58.9 million, compared to $57.7 million for the same period in 2024.
Research and development expenses for the quarter: $13.6 million (down $5.2 million year-over-year), primarily due to fewer milestone payments and prioritization of endometrial cancer.
General and administrative expenses for the quarter: $6.0 million, consistent year-over-year.
Cash, cash equivalents, and investments as of September 30, 2025: $134.4 million.
Outlook and guidance
Existing cash and investments expected to fund operations into Q2 2027.
Updates on ACR-368 trial and confirmatory trial design, as well as initial clinical data from ACR-2316 Phase 1, anticipated in H2 2025.
Advancing a new cell cycle drug discovery program toward candidate nomination in 2025.
Anticipates continued operating losses and increased expenses as clinical and preclinical programs advance.
Additional funding will be required to support long-term growth and development plans.
AP3 insights for ACR-368 ULDG combination
ACR-2316 clinical response in specific tumors
ACR-368 other tumor types: current status
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Acrivon Therapeutics earnings date
Q4 202527 Mar, 2026
Next Acrivon Therapeutics earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company advances drug candidates tailored to the predicted sensitivity of tumors to specific medicines. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage